Skip to main content

Table 2 Clinical characteristics of patients who did or did not receive antiplatelet agents

From: Patency with antiplatelet treatment after vascular access intervention therapy: a retrospective observational study

  Antiplatelet group Non-antiplatelet group p value
Number 31 28  
Age 73 (68–78) 71 (58.5–80) 0.27
Older age (%) 54.8 42.9 0.44
Sex (male, %) 80.7 64.3 0.22
Etiology of ESRD (%)
 DN 48.4 32.1 0.20
 NS 25.8 21.4 0.69
 CGN 9.7 21.4 0.21
 ADPKD 3.2 0 0.34
 IgAN 6.5 3.6 0.62
 Other or unknown 6.5 21.4 0.093
Smoking history (%) 80.7 46.4 0.008
DM (%) 61.3 53.6 0.60
Dyslipidemia (%) 74.2 39.3 0.009
CVD (%) 80.7 25.0 < 0.001
 IHD 58.1 10.7 < 0.001
 CHF 16.1 10.7 0.54
 Stroke 22.6 0 0.007
PAD (%) 22.6 3.6 0.55
RASI (%) 45.2 60.7 0.30
Statin (%) 29.0 75.0 < 0.001
Warfarin (%) 6.5 10.7 0.67
ESA
 Epoetin α or β (IU/week) 3750.0 ± 1068.5 2750.0 ± 975.4 0.51
 Darbepoetin α (μg/week) 33.1 ± 9.7 47.4 ± 9.4 0.29
 CERA (μg/2 week) 50 75
Hb (g/dl) 10.6 ± 0.3 10.1 ± 0.29 0.28
Platelet (× 103/μl) 19.8 ± 1.2 17.9 ± 1.3 0.28
PT-INR 1.0 ± 0.1 1.1 ± 0.1 0.50
CRP (mg/dl) 0.6 ± 0.3 0.8 ± 0.3 0.71
Dialysis duration (month) 31.8 ± 33.2 20.8 ± 27.0 0.42
AVF anastomosis type (%)
 Radiocephalic 71.0 92.9 0.031
 Brachiocephalic 25.8 7.1 0.056
 Radiobasilic 3.2 0 0.34
Quantity of blood flow (ml/min) 194.1 ± 6.5 190 ± 7.6 0.69
Flow volume (ml/min)
 Before VAIVT 461.8 ± 86.1 373.1 ± 88.5 0.47
 After VAIVT 816.2 ± 172.9 872.1 ± 177.9 0.82
VAF
 Thrombosis (%) 19.4 10.7 0.48
Adverse event (%)
 Serious bleeding event
  Intracranial 0 0
  Gastrointestinal 0 0
 CVD event after VAIVT
  IHD 19.4 3.6 0.061
  CHF 6.5 3.6 0.62
  Stroke 3.2 0 0.34
  1. We defined individuals aged > 71 years as “the older age”
  2. ESRD end-stage renal disease, DN diabetic nephropathy, NS nephrosclerosis, CGN chronic glomerulonephritis, ADPKD autosomal dominant polycystic kidney disease, IgAN IgA nephropathy, DM diabetes mellitus, CVD cardiovascular disease, IHD ischemic heart disease, CHF congestive heart failure, PAD peripheral artery disease, RASI renin–angiotensin–aldosterone system inhibitor, ESA erythropoiesis-stimulating agent, CERA continuous erythropoietin receptor activator, AVF arteriovenous fistula, VAIVT vascular access intervention therapy, VAF vascular access failure